Zura Bio Limited (ZURA)
Zura Bio Statistics
Share Statistics
Zura Bio has 68.38M shares outstanding. The number of shares has increased by 7.37% in one year.
| Shares Outstanding | 68.38M |
| Shares Change (YoY) | 7.37% |
| Shares Change (QoQ) | 4.72% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 46.35M |
| Failed to Deliver (FTD) Shares | 1.34K |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
The latest short interest is 4.99M, so 7.64% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short % of Shares Out | 7.64% |
| Short % of Float | 10.6% |
| Short Ratio (days to cover) | 8.08 |
Valuation Ratios
The PE ratio is -4.14 and the forward PE ratio is -2.2. Zura Bio's PEG ratio is 0.06.
| PE Ratio | -4.14 |
| Forward PE | -2.2 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | 1.28 |
| P/FCF Ratio | -6.67 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zura Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.16, with a Debt / Equity ratio of 0.
| Current Ratio | 9.16 |
| Quick Ratio | 9.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.51M |
| Employee Count | 30 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -7.02M |
| Effective Tax Rate | 13.39% |
Stock Price Statistics
The stock price has increased by -60.07% in the last 52 weeks. The beta is 0.06, so Zura Bio's price volatility has been higher than the market average.
| Beta | 0.06 |
| 52-Week Price Change | -60.07% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 40.37 |
| Average Volume (20 Days) | 362.34K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -55.19M |
| Net Income | -45.39M |
| EBITDA | -55.19M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 176.5M in cash and 0 in debt, giving a net cash position of 176.5M.
| Cash & Cash Equivalents | 176.5M |
| Total Debt | 0 |
| Net Cash | 176.5M |
| Retained Earnings | -155.9M |
| Total Assets | 179.53M |
| Working Capital | 159.23M |
Cash Flow
In the last 12 months, operating cash flow was -28.08M and capital expenditures -75K, giving a free cash flow of -28.15M.
| Operating Cash Flow | -28.08M |
| Capital Expenditures | -75K |
| Free Cash Flow | -28.15M |
| FCF Per Share | -0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ZURA is $15, which is 1182.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 1182.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 1.29 |
| Piotroski F-Score | 4 |